The immune checkpoint inhibitor (ICI), Atezolizumab (PD-L1 inhibitor), in combination with Bevacizumab (VEGF antibody), has received FDA approval as a first-line treatment for unresectable HCC [3]. Here, CD274 is linked to hepatocellular carcinoma.